Prevalence of Fabry disease in Japanese population with left ventricular hypertrophy

Prevalence of Fabry disease in Japanese population with left ventricular hypertrophy - Fabry cardiomyopathy screening study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000015523

Enrollment

4000

Registered

2014-10-26

Start date

2014-08-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

left ventricular hypertrophy Fabry disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: left ventricular hypertrophy; more than 12mm thickness of septum and/or posterior wall

Exclusion criteria

Exclusion criteria: Patient with sarcomeric gene mutation Patient with strongly affected hydrodynamics caused by severe valvular disease or congenital heart disease

Design outcomes

Primary

Measure	Time frame
enzymatic activity of alpha-galactsidase	—

Secondary

Measure	Time frame
measurement of Lyso-Gb3	—

Countries

Japan

Contacts

Public ContactTakeshi Akasaaka

Shonan Kamakura General Hospital Department of Cardiology

akasaka-cba@umin.ac.jp0467-46-1717

Outcome results